This is the authors' abstract. We don't add key points for this paper.
Background: expression across breast cancer molecular subtypes and assessed its prognostic and predictive significance. Methods: mRNA expression, co-expressed signaling pathways, and associations with therapeutic response. Results: expression was not predictive of response to tamoxifen or trastuzumab. Conclusion: expression is associated with breast cancer recurrence and poor clinical outcomes, supporting its potential role as a prognostic biomarker and candidate therapeutic target.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: